SCHEMBL6103197

SCHEMBL6103197

CCCN(CC(C)C)c1ccc(Br)cc1C=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH3A1 P30838 4/20 0.47
ALDH1A3 P47895 3/20 0.47
ALDH1A1 P00352 2/20 0.47
ERN1 O75460 1/20 0.38
CYP2A6 P11509 2/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
PLA2G1B P04054 1/20 0.32
ATG4B Q9Y4P1 1/20 0.32
HTR1D P28221 1/20 0.32
CRHR1 P34998 2/20 0.32
CCR5 P51681 1/20 0.31
HPGD P15428 1/20 0.31
MAPT P10636 2/20 0.30
LMNA P02545 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6105579 0.90 ERN1 (0.43) ALDH3A1ALDH1A3ALDH1A1ERN1CYP2A6
SCHEMBL6104215 0.89 ALDH1A3 (0.48) ALDH3A1ALDH1A3ALDH1A1ERN1CYP2A6
SCHEMBL6104859 0.82 ALDH1A1 (0.39) ALDH3A1ALDH1A3ALDH1A1MAPTLMNA
SCHEMBL6104863 0.82 ALDH1A1 (0.39) ALDH3A1ALDH1A3ALDH1A1MAPTLMNA
SCHEMBL6517350 0.82 PTGDR2 (0.40) ALDH3A1ALDH1A3ALDH1A1ERN1PTGDR2
SCHEMBL3157614 0.81 PTGDR2 (0.40) ALDH1A3ALDH1A1ERN1PTGDR2MAPT
SCHEMBL6103005 0.81 ERN1 (0.43) ALDH3A1ALDH1A3ALDH1A1ERN1CYP2A6
SCHEMBL6102737 0.79 ALDH1A3 (0.46) ALDH3A1ALDH1A3ALDH1A1ERN1CYP2A6
SCHEMBL3172718 0.79 PTGDR2 (0.35) ERN1PTGDR2HPGDMAPTLMNA
SCHEMBL6350449 0.76 ALDH3A1 (0.46) ALDH3A1ALDH1A3ALDH1A1ERN1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160864-A1 Acrylamide derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-20 US disclosed
EP-1593673-A1 ACRYLAMIDE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160864-A1 Acrylamide derivative, process for producing the same, and use CCR5, MSR1, CCR2 ALDH3A1 747/4885ALDH1A3 3397/4885ALDH1A1 1414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.